Semaglutide channel chokes on Rs 100cr excess stock as April generic rush fades
India's Rs 2,000cr obesity drug market is digesting a Rs 100cr inventory overhang after May sales cooled. Stockists are sitting on 50-60 days of semaglutide stock and have paused procurement, per AIOCD-Pharmarack data. Eli Lilly's Mounjaro held the top spot at Rs 136cr, while category value grew just 6% m-o-m against 12% unit growth.
India's semaglutide therapy market faces Rs 100 crore inventory overhang as May sales slowed sharply after April's generic-launch surge. Stockists holding 50-60 days stock paused procurement; Eli Lilly's Mounjaro remained top seller at Rs 136 crore.